|January 23, 2014|
|09:09 EDT||BIIB, ISIS||Deutsche Bank's biotech analysts hold an analyst/industry conference call|
Biotech Analysts Karnauskas and Young discuss the risk/reward in the 1Q14 for Isis Pharmaceuticals (ISIS) and Biogen Idec (BIIB) for treating Spinal Muscular Atrophy (SMA) on an Analyst/Industry conference call to be held on January 23 at 10 am.
News For BIIB;ISIS From The Last 14 Days
Check below for free stories on BIIB;ISIS the last two weeks.
|August 28, 2014|
|07:05 EDT||ISIS||Isis Pharmaceuticals initiates ISIS-APOCIII Phase 3 study|
Subscribe for More Information
|August 27, 2014|
|09:08 EDT||BIIB||Nektar could see $100M in revenue from Baxter drug, says Roth Capital|
Roth Capital believes that Baxter's (BAX) BAX-855 drug delivered compelling Phase III data, and the firm expects the drug to compete effectively against Biogen's (BIIB) Eloctate. Roth expects BAX-855 to launch in 1Q16 and believes it could generate up to $100M in annual revenue for Nektar. The firm keeps a $21 price target and Buy rating on Nektar.
|08:21 EDT||BIIB||NICE recommends Tecfidera for multiple sclerosis|
Dimethyl fumarate is recommended as a possible treatment for people with active relapsing-remitting multiple sclerosis that isn't highly active or rapidly evolving severe relapsing-remitting multiple sclerosis, the U.K.'s National Institute for Health and Care Excellence stated in guidance posted to its website. Reference Link
|August 26, 2014|
|11:21 EDT||BIIB||Biogen added to short term buy list at Deutsche Bank|
|August 22, 2014|
|12:39 EDT||BIIB, ISIS||These five companies will benefit from increased ALS awareness, MarketWatch says|
A recent surge in funding for Lou Gehrig's disease, or ALS, caused by the Ice Bucket challenge that is widespread on social media outlets, will benefit five pharmaceutical companies that are involved in the development of a cure for ALS, according to MarketWatch. The companies that are or have been involved in developing a treatment for ALS include Biogen Idec (BIIB), Avanir Pharmaceuticals (AVNR), Isis Pharmaceuticals (ISIS), Sanofi (SNY), and Bristol-Myers Squibb (BMY), MarketWatch added. Reference Link
|August 15, 2014|
|18:35 EDT||BIIB||Biogen PLEGRIDY approved in U.S. for treatment of multiple sclerosis|
Biogen Idec announced that the FDA has approved PLEGRIDY, a new treatment for people with relapsing forms of multiple sclerosis, or RMS. PLEGRIDY is dosed once every two weeks and can be administered subcutaneously with the PLEGRIDY PEN, a new, ready-to-use autoinjector, or a prefilled syringe. The FDA approval of PLEGRIDY is based on results from one of the largest pivotal studies of beta interferon conducted, ADVANCE, which involved more than 1,500 MS patients.
|07:01 EDT||BIIB, ISIS||Isis Pharmaceuticals earns $2M from advancement of ISIS-SMN from Biogen |
Isis Pharmaceuticals (ISIS) announced that it has earned a $2M milestone payment from Biogen (BIIB) related to the advancement of the ongoing open-label extension study of ISIS-SMNRx in children with spinal muscular atrophy.